-
The Facebook (FB) IPO - Don't Believe The Hype
No doubt Friday's Facebook (FB) IPO marks an historical moment in the history of the tech and financial sectors, but that's all that this much-anticipated event might turn out to be - a moment in time that, at the end of the day, means little in the grand scheme of things, other than that a great campaign of hype can spark enough emotional momentum to create an insane amount of wealth for those involved in the hype campaign.
Remember when shares of Sirius (SIRI) ran to over nine bucks solely because Howard Stern agreed to join the company for half a billion dollars? That hype made a whole lot of investors rich - while the numbers were never there to support the price - but when reality came crashing down on those that believed the hype, the share price followed south...
-
Celsius Holdings' (CELH) First Quarter Numbers May Have Company Positioned For Growth
Another stable earnings report may have once again positioned Celsius Holdings (CELH) as a solid growth play to consider as the company's calorie burning, pre-workout beverage gains traction in its niche market.
The reported sales of $2.5 million for the first quarter of 2012 were up from a number of $2.2 million during the same quarter last year, but more significantly was the increase of 41% over the fourth quarter of 2011. Returns and stockpile write-off has hampered the numbers at times during the past year, but the numbers announced last week may have provided a turning point that the company can use to build momentum...
-
The Case For Keryx Biopharmaceuticals (KERX) - Analyst Upgrade May Be Justified
An analyst upgrade last week and renewed investor interest in Keryx Biopharmaceuticals (KERX) had shares heavily on the move over the past week, a move initially sparked, in part, by positive Phase III data for Zerenex in Japan. The KERX run culminated in a renewed push through the two dollar mark before a mid-week stall left shares sitting just below that mark.
The disappointing announcement of a Perifisone Phase III failure in early April sent shares plummeting from near the five dollar mark to below $1.50 as the short term catalyst traders bailed out and created an air of panic around the potential of the Keryx story moving forward, but the upgrade last week by Ladenburg Thalmann to 'Buy' from 'Neutral' reinvigorated some new life into the KERX share price and allowed investors - who by now have well digested the Perifisone news - to take a fresh look at the potential of Zerenex...
-
Weekly Stock Watch, Week of May 14: SIRI, PBTH, KERX, HGSI, CELH, JPM, C, BAC, M, JWN, JCP, SKS, TGT, FB, IMSC, TROV, ARNA, VVUC, NEPH, MNKD, ACTC, CVM, AGEN, DIS, SGYP, TTNP
At the conclusion of each week,VFC's Stock House examines some news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. Although focusing intently on the biotech and healthcare sectors, due attention is also given to potential market-moving or game-changing companies in a broad variety of sectors and industries. The 'Weekly Stock Watch' will also introduce new companies for coverage and identify some stocks that may have entered 'buy territory'.
Huge trading losses at JP Morgan Chase (JPM) that sent company shares spiraling by 10% on Friday accentuated an already lackluster trading week in the broad markets and left the door wide open for another volatile week ahead. Combine that sentiment with growing uncertainty in Europe, where recent Greek and French elections have the potential to reshape the look of austerity and other measures undertaken by European governments in an attempt to maintain control over the Euro Zone's teetering economy, and investors may see even more of a reason to sell out and hold on the sidelines until some normalcy returns to the sinking global sentiment - a sentiment that has some predicting will bring parity between the euro and the dollar.
There could, however, be a savior in the works...
-
Mid-Week Stock Watch: HGSI, TROV, ONTY, SIRI, PIMO
Some hot stocks and stories to watch mid-week...
Human Genome Sciences (HGSI):
Long on potential but short on results has been the name of the game for the lupus-treating drug Benlysta since its commercial launch last year, but an offer last month by Human Genome's partner GlaxoSmithKline (GSK) to purchase the company has not only reinvigorated investor interest in the company's pipeline, but it also sparked a quick rally in the HGSI share price that returned investors about a double overnight.
The swift rally placed HGSI right in line with the valuation of Glaxo's offer, which stood at $2.6 billion and a $13 share price...
-
The Dendreon (DNDN) Dip: Should Investors Jump In Or Out?
On the heels of Dendreon's (DNDN) first quarter earnings announcement on Monday that was - for the most part - in line with expectations, DNDN shares spiraled downward throughout the trading day on Tuesday and closed twenty five percent lower than the previous day's closing price. The quick drop returned shares right back to near the bottom of the stock's trading range over the past few quarters and dampered the expectations of investors looking for a revival of the 'Golden Age' of Dendreon that would ignite another price run and possibly challenge the $40 levels seen shortly after the FDA's approval of Provenge a couple of years back...
-
Stocks On The Move: PBTH, DNDN, TROV, AGEN
It has been a rough couple of days for the markets as huge uncertainty in Europe and a stalling US recovery send shockwaves through the investing world, but there are still a few companies out there making news that are worth keeping an eye on. The broad downturn could also open up some solid buying opportunities that have the potential to turn into quick rebound stories once the markets recover.
Here's a little bit of the good, the bad and the ugly from the week so far, and some possible good deals there for the grabbing...Prolor Biotech (PBTH): Prolor Biotech (PBTH) opened the week as a stock on the move and continued that pattern on Tuesday with an early seven percent price rise on heavier-than-usual volume sparked by a Monday news report announcing positive top-line results from a Phase II four-month treatment extension study of hGH-CTP growth hormone deficient adults...
-
Weekly Stock Watch: DNDN, DIS, FCEL, SGYP, IMUC, IMSC, SIGA, HGSI, CPST, GSK, GLTC, TLON, BVTI
At the conclusion of each week, VFC's Stock House examines some news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. Although focusing intently on the biotech and healthcare sectors, due attention is also given to potential market-moving or game-changing companies in a broad variety of sectors and industries. The 'Weekly Stock Watch' will also introduce new companies for coverage and identify some stocks that may have entered 'buy territory'.
European elections, the people's protests of Putin in Russia and Disney's (DIS) 'The Avengers' dominated headlines over the weekend. As the Russian people displayed their dismay with the re-election of Vladimir Putin in Russia, France's Nicolas Sarkozy was the latest European politician to receive the boot from voters still feeling the pain of the global economic meltdown a few years ago - and incumbents in Greece didn't fare much better...
-
Key Appointment Marks Another Win For Synergy Pharmaceuticals (SGYP)
Synergy Pharmaceuticals (SGYP) has been a stock on the move over the past few weeks based on the the billion-dollar potential of its pipeline and increasing analyst coverage that has attracted a significant amount of new trading volume. Synergy's short and long term prospects have also been strengthened by a recent news development of a competitor setback that may help the company play catch up to the developmental edge held by rival Ironwood Pharmaceuticals (IRWD). Ironwood's competing product is slated to make it to market first, although Synergy's product has thus far not caused any side effects, while Ironwood's has...
-
Immunocellular Therapeutics (IMUC): Any Pullback May Mean Opportunity
Immunocellular Therapeutics (IMUC) has already posted some significant gains since the opening days of 2012 - easily blowing through the two dollar mark before hitting three for a time - and although the stock has held strong through recent bouts of broad market volatility, shares experienced a mild pullback over the past few trading sessions. Any such moves in line with Monday's four percent dip, however, may be viewed as nothing more than a potential opportunity to accumulate as IMUC may posess enough early-year momentum to not only sustain the current higher prices, but also to propel shares higher as numerous still-pending developments play out...
-
Volume Watch: Premier Alliance Group (PIMO), Amazon (AMZN), Barnes & Noble (BKS), Synergy Pharmaceuticals (SGYP)
Monday proved to be a ho-hum day for the broad markets, with not much excitements as the major markers trading slightly in the red for the duration of trading. There were, however, some stocks on the move making noise while a few nice volume plays were worth noting because, as they say, many times volume precedes price...
Premier Alliance Group (PIMO) was a stock to watch last week as trading volume started to pick up, and that volume boost carried into the new trading week, too, as PIMO shares traded on well more than triple the daily average to open the new trading week. As previously discussed, Premier has been growing its customer base over the past few years and increasing its revenues and earnings, as well, all while completing some key acquisitions and mergers that have thrust the company into the heart of one of the most rapidly growing sectors - energy efficiency and devising methods and programs to maximize that efficiency...
-
Stock Watch: Cel-Sci Corp (CVM) And Synergy Pharmaceuticals (SGYP)
Shares of Cel-Sci Corp (CVM) were up by roughly eight percent for most of the day on Monday, with no news being released in conjunction with the price rise and not much more than the average volume trading throughout the day. Cel-Sci did receive mention on a couple of popular news and finance related websites, however, as Fox Business and Forbes.com noted the gap up and early price action of the company's stock and highlighted the performance as one of the best in biotech.
Another recent high-flyer made the Forbes report as well, as shares of Synergy Pharmaceuticals (SGYP) opened the week with a fourteen percent price spike...
